The 2026 LiBBY trial tested a purified THC-plus-CBD oil for agitation in late-stage dementia. It established strong agitation relief with overall side effects near placebo, but left serious infections and deaths uncertain for family caregivers. Agitation here means persistent restlessness, verbal outbursts, and aggression. These behaviors drain families and hospice staff day and night.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What LiBBY tested and who joined
- How much agitation eased
- What everyday safety looked like
- Why serious events stay uncertain
- What caregivers should avoid now
What LiBBY tested and who joined
LiBBY enrolled 120 hospice-eligible patients with Alzheimer's or other dementia plus agitation. Ten U.S. sites ran a 12-week randomized, double-blind, placebo-controlled Phase 2 study with home visits.
The Alzheimer's Association says it was presented July 14, 2026, at AAIC London in its AAIC summary. Active treatment was 2 mg THC plus 100 mg CBD twice daily. NeurologyLive describes the oil as a purified pharmaceutical formula, distinct from dispensary products.
How much agitation eased
Agitation scores fell 10.61 points on treatment versus 4.35 on placebo at week 2. MIMS reporting on the AAIC presentation notes the difference was highly significant and held through week 12 in its trial report. The week-2 p-value was 0.0004.
Global improvement reached 87.2% versus 23.6% on placebo at week 12. At week 2, response was 83.9% versus 30.5%. NeurologyLive reports the benefit touched patients plus family and professional caregivers managing restlessness and aggression.
What everyday safety looked like
Overall adverse events were close: 46.7% on treatment and 42.4% on placebo. News-Medical, reporting Pennington and ACTC results, says most were infections and gut disorders expected in end-of-life dementia in its trial coverage.
Investigators judged no serious event related to study drug. That call calms daily-use fears but does not explain the serious-event gap.
Why serious events stay uncertain
Serious events were higher with treatment, 23.3% versus 11.9%. NeurologyLive reports serious infections at 11.7% versus 1.7% and deaths at 13.1% versus 5.1% in its safety analysis.
These patients were frail and hospice-eligible, so background illness can mimic drug harm. Pennington Biomedical notes the small Phase 2 size, short 12-week course, and topline conference status require larger confirmatory trials before general use.
What caregivers should avoid now
Do not replace the study formula with store CBD or dispensary cannabis. NeurologyLive stresses safety and efficacy apply only to the supervised purified dose and monitoring used in LiBBY. Use the wait for larger trials to tighten daily care and communication.
- Bring the exact LiBBY dose to each hospice visit and ask how it differs from store oils.
- Track agitation triggers, sleep, appetite, falls, fever, and breathing changes daily.
- Call the hospice nurse promptly for fever, new cough, vomiting, or sudden decline.
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: What Is Established and What Remains Uncertain for Family Caregivers
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: What Is Established and What Remains Uncertain for Family Caregivers
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: What Is Established and What Remains Uncertain for Family Caregivers
